SCHEMBL17309393

SCHEMBL17309393

CCN1C(=O)/C(=C/c2cc(I)c(O)c(OC)c2)S/C1=N/c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA9 Q16790 5/20 0.60
▸ PTPN1 P18031 7/20 0.59
▸ ACP1 P24666 6/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ PKM P14618 1/20 0.59
▸ AKR1B1 P15121 1/20 0.56
▸ MGAM O43451 2/20 0.56
▸ CA12 O43570 2/20 0.56
▸ CA1 P00915 2/20 0.56
▸ CA2 P00918 2/20 0.56
▸ POLB P06746 2/20 0.56
▸ PSMD14 O00487 1/20 0.56
▸ FAAH O00519 1/20 0.55
▸ PTPN2 P17706 4/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19481523 1.00 CA9 (0.60) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL17309286 0.90 MEN1 (0.66) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL11996403 0.84 PTPN1 (0.73) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL11996404 0.84 PTPN1 (0.73) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL3891157 0.81 PTPN1 (0.59) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL3891749 0.81 PTPN1 (0.59) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL3891738 0.81 PTPN1 (0.59) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL12013726 0.80 CA9 (0.56) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL3891123 0.80 CA9 (0.56) CA9PTPN1ACP1MEN1KMT2A
SCHEMBL3891119 0.80 CA9 (0.56) CA9PTPN1ACP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148541-B1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIV BERN (CH) 2020-09-02 — — EP disclosed
US-10300048-B2 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation UNIVERSITAT BERN (CH) 2019-05-28 — — US disclosed
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-10-19 — — US disclosed
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-10-19 — — US disclosed
EP-2952188-A1 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation Universität Bern (CH) 2015-12-09 — — EP disclosed
WO-2015181336-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10300048-B2 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation SLC18A2, AANAT, CNR2 CA9 4726/4885PTPN1 3274/4885ACP1 4207/4885
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION SLC18A2, AANAT, CNR2 CA9 4726/4885PTPN1 3274/4885ACP1 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback